Daily Respiratory Research Analysis
Analyzed 91 papers and selected 3 impactful papers.
Summary
Three mechanistic respiratory studies stand out: lactylation of S100A9 drives IL-1β transcription and sepsis-related lung injury, copper ionophore-induced cuproptosis selectively eliminates myofibroblasts to reverse pulmonary fibrosis, and nebulized hUCMSC-derived exosomes protect endothelial mitochondria to attenuate ALI by suppressing ferroptosis. Together, they spotlight immunometabolism, regulated cell death, and inhaled cell-free therapeutics as converging avenues for ARDS and fibrosis.
Research Themes
- Immunometabolic control of macrophage-driven lung injury
- Targeting regulated cell death pathways (cuproptosis/ferroptosis) in pulmonary fibrosis and ALI
- Inhaled, cell-free regenerative therapeutics for ARDS
Selected Articles
1. S100A9 lactylation facilitated sepsis-related acute respiratory distress syndrome via promoting transcription activation of IL-1β in macrophages.
S100A9 undergoes lactylation at K4 and K94 during sepsis, which promotes its nuclear translocation and interaction with CEBPB to drive IL-1β transcription in macrophages, exacerbating sepsis-related acute lung injury. Genetic deletion of S100A9 mitigated inflammatory responses and lung injury, identifying S100A9 lactylation as a targetable immunometabolic switch.
Impact: Reveals a previously unrecognized post-translational modification controlling macrophage inflammatory output in ARDS, linking lactylation to transcriptional programming and identifying tractable nodes for intervention.
Clinical Implications: Pharmacologically modulating S100A9 lactylation or its interaction with CEBPB could reduce IL-1β-driven inflammation in sepsis-related ALI/ARDS; it supports trials of IL-1 pathway and metabolic regulators in immunoparalysis-prone patients.
Key Findings
- S100A9 is lactylated at K4 and K94 in septic patients and CLP mice.
- Lactylation promotes S100A9 nuclear translocation and binding to CEBPB, enhancing IL-1β transcription.
- S100A9 knockout reduces inflammatory responses and lung injury in sepsis-induced ALI models.
Methodological Strengths
- Use of human septic samples and CLP mouse models with site-specific PTM mapping by mass spectrometry
- Mechanistic validation via mutagenesis, co-immunoprecipitation, and luciferase reporter assays
Limitations
- Preclinical nature without interventional proof-of-concept in humans
- Sample sizes and replication across diverse sepsis etiologies not detailed in the abstract
Future Directions: Develop selective inhibitors of S100A9 lactylation or disruptors of S100A9–CEBPB interaction; test IL-1β/CEBPB-targeted and metabolic modulators in translational sepsis-ARDS models with biomarker-guided stratification.
BACKGROUND: Sepsis is a severe inflammatory condition often complicated by acute lung injury (ALI) with limited therapeutic options. S100 Calcium Binding Protein A9 (S100A9) as an alarmin is highly elevated in sepsis. We observed that S100A9 was lactylated in the lung tissues of septic mice, the role of which in regulating sepsis-related ALI remains unknown. METHODS: S100A9 lactylation sites were identified in septic patients and CLP mice using immunoprecipitation and mass spectrometry. Mechanistic studies employed mutagenesis, co-immunoprecipitation, and luciferase assays. RESULTS: In this study, we confirmed that S100A9 was lactylated at K4 and K94 in se
2. Targeting myofibroblast copper vulnerability reverses pulmonary fibrosis via METTL3-directed STAT6 m6A driving cuproptosis.
Copper ionophores reverse fibrosis in bleomycin-injured lungs by inducing cuproptosis that selectively eliminates apoptosis-resistant myofibroblasts. Mechanistically, an METTL3–STAT6–m6A–Nrf2 axis defines a druggable checkpoint controlling myofibroblast vulnerability to copper-dependent cell death.
Impact: Introduces cuproptosis as a tractable death pathway to deplete pathogenic myofibroblasts in IPF, addressing a central therapeutic gap beyond antifibrotic slowdown.
Clinical Implications: Supports exploration of copper ionophores or pathway modulators as anti-fibrotic agents, with biomarker strategies around STAT6/METTL3 to enrich responsive IPF phenotypes.
Key Findings
- Copper ionophores reduced lung collagen and selectively eliminated α-SMA+ myofibroblasts in bleomycin-induced fibrosis.
- STAT6 fibroblast-conditional knockout and METTL3/IGF2BP2 perturbations mapped an METTL3–STAT6–m6A–Nrf2 mechanism for cuproptosis sensitivity.
- Therapeutic targeting of copper vulnerability reversed established fibrotic remodeling.
Methodological Strengths
- In vivo efficacy in established bleomycin fibrosis with complementary primary fibroblast assays
- Genetic dissection using fibroblast-specific STAT6 cKO and METTL3/IGF2BP2 gain/loss-of-function
Limitations
- Bleomycin model may not fully capture chronic human IPF pathobiology
- Safety and pharmacokinetics of copper ionophores in lungs require careful evaluation
Future Directions: Define therapeutic window and delivery strategies for lung-targeted copper ionophores; validate STAT6/METTL3-based biomarkers and test combinations with current antifibrotics in large-animal models.
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) remains a fatal disease due to apoptosis-resistant myofibroblasts driving pathological extracellular matrix deposition. Current therapies fail to directly eliminate these cells, and cuproptosis-a copper-dependent cell death pathway-remains unexplored in pulmonary fibrosis. OBJECTIVES: We aimed to investigate whether copper ionophores induce selective myofibroblast death via cuproptosis and evaluate their antifibrotic effects. The study further explored the underlying molecular mechanisms involving STAT6 m6A methylation. METHODS: Copper ionophores were administrated to bleomycin-induced fibrotic mice to evaluate their antifibrotic effects and induction of cuproptosis. Primary fibroblasts isolated from mouse lungs were further employed for in vitro analysis. STAT6 fibroblast-conditional knockout (cKO) mice, as well as gain- and loss-of-function studies targeting METTL3 and IGF2BP2 were employed to explore potential mechanism. RESULTS: Our results show that copper ionophores significantly reduced lung collagen and eliminated α-SMA
3. hUCMSC-exosomes attenuate acute lung injury by inhibiting ferroptosis in pulmonary microvascular endothelial cells through ribosomal protein RPS11 upregulation.
Nebulized hUCMSC-derived exosomes are internalized by lung microvascular endothelium, restore mitochondrial translation via RPS11 upregulation, and suppress endothelial ferroptosis, thereby attenuating ALI in an inhalation model. Multi-omics and functional knockdown pinpoint RPS11 as a key mediator of the exosomal protective program.
Impact: Demonstrates a noninvasive, cell-free, inhaled therapy mechanistically targeting ferroptosis and mitochondrial translation in pulmonary endothelium, a pivotal ALI/ARDS compartment.
Clinical Implications: Supports development of inhaled exosome therapeutics for ARDS, with RPS11 and ferroptosis biomarkers as pharmacodynamic readouts; informs endothelial-centric strategies to preserve barrier integrity.
Key Findings
- Nebulized hUCMSC-exosomes are internalized by pulmonary microvascular endothelial cells and reduce histologic injury, edema, inflammation, and ferroptosis in ALI.
- Exosomes transfer mitochondrial components and upregulate RPS11, enhancing mitochondria-encoded protein translation and restoring endothelial mitochondrial function.
- RPS11 knockdown abrogates exosome-mediated suppression of ferroptosis and mitochondrial rescue, identifying RPS11 as a key mediator.
Methodological Strengths
- Inhalation delivery with endothelial uptake confirmed and phenotype rescue across multiple ALI models
- Multi-omics mitochondria-focused proteomics with functional RPS11 knockdown validation
Limitations
- Preclinical study without human safety/PK data for inhaled exosomes
- Exosome heterogeneity and manufacturing/scale-up considerations remain unaddressed
Future Directions: Define dose, schedule, and release criteria for GMP-grade inhaled exosomes; evaluate RPS11/ferroptosis biomarkers in large-animal ARDS and plan early-phase human trials.
BACKGROUND: Human umbilical cord mesenchymal stem cell-derived exosomes (hUCMSC-Exos) are a promising treatment for acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), but traditional delivery methods have limitations. Therefore, this study presents a noninvasive therapeutic approach for ALI/ARDS, offering new mechanistic insights and identifying potential therapeutic targets. RESULTS: We established a nebulized LPS-induced ALI model that was characterized by diffuse lung injury and high homogeneity. Following inhalation, hUCMSC-Exos were observed to be internalized by pulmonary microvascular endothelial cells. Analysis revealed that hUCMSC-Exos alleviated ALI by reducing the severity of histological damage, pulmonary oedema, lung inflammation and ferroptosis. Additionally, hUCMSC-Exos improved the mitochondrial function of human pulmonary microvascular endothelial cells (HPMECs) via the transfer of mitochondrial components. Subsequent proteomic sequencing of mitochondria isolated from HPMECs receiving different treatments revealed the significant differential expression of ribosomal proteins among the groups. The most significantly upregulated protein, RPS11, was identified as a key mediator; its knockdown blocked the ability of hUCMSC-Exos to suppress ferroptosis and restore mitochondrial function in HPMECs. Mechanistically, hUCMSC-Exos exert their effects by enhancing mitochondria-encoded protein translation. CONCLUSIONS: We report a mechanism whereby hUCMSC-Exos upregulate RPS11 to promote mitochondria-encoded protein translation, rescuing mitochondrial function, inhibiting ferroptosis in HPMECs, and ultimately alleviating ALI. Validated across multiple models and supported by multi-omics analyses, our findings collectively establish nebulized hUCMSC-Exos as a promising cell-free therapy targeting mitochondrial homeostasis in HPMECs for the treatment of ALI.